Limits...
Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts

View Article: PubMed Central - PubMed

ABSTRACT

Famitinib (SHR1020), a novel multi-targeted tyrosine kinase inhibitor, has antitumor activity against several solid tumors via targeting vascular endothelial growth factor receptor 2, c-Kit and platelet-derived growth factor receptor β. The present study investigated famitinib's activity against human gastric cancer cells in vitro and in vivo. Cell viability and apoptosis were measured, and cell cycle analysis was performed following famitinib treatment using 3-(4,5-dimethylthiazol −2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay, flow cytometry, terminal deoxynucleotidyl transferase dUTP nick end labeling assay and western blotting. Subsequently, cluster of differentiation 34 staining was used to evaluate microvessel density. BGC-823-derived xenografts in nude mice were established to assess drug efficacy in vivo. Famitinib inhibited cell proliferation by inducing cell cycle arrest at the G2/M phase and caused cell apoptosis in a dose-dependent manner in gastric cancer cell lines. In BGC-823 xenograft models, famitinib significantly slowed tumor growth in vivo via inhibition of angiogenesis. Compared with other chemotherapeutics such as 5-fluorouracil, cisplatin or paclitaxel alone, famitinib exhibited the greatest tumor suppression effect (>85% inhibition). The present study demonstrated for the first time that famitinib has efficacy against human gastric cancer in vitro and in vivo, which may lay the foundations for future clinical trials.

No MeSH data available.


Inhibition of cell growth mediated by famitinib in BGC-823 and MGC-803 cell lines. Cells were exposed to famitinib for 24, 48 and 72 h, and cell viability was diminished in a dose-dependent manner.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998225&req=5

f1-ol-0-0-4909: Inhibition of cell growth mediated by famitinib in BGC-823 and MGC-803 cell lines. Cells were exposed to famitinib for 24, 48 and 72 h, and cell viability was diminished in a dose-dependent manner.

Mentions: BGC-823 and MGC-803 cells were treated with famitinib (0, 0.6, 1.25, 2.5, 5.0, 10.0 and 20.0 µM) for 24, 48 and 72 h, followed by MTS assay. Famitinib inhibited cell growth in a dose-dependent manner (Fig. 1). The half maximal inhibitory concentration (IC50) values of famitinib in BGC-823 and MGC-803 cells were 3.6 and 3.1 µM, respectively. Based on these results, the IC50 and 1/2 IC50 were used for in vitro experiments.


Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
Inhibition of cell growth mediated by famitinib in BGC-823 and MGC-803 cell lines. Cells were exposed to famitinib for 24, 48 and 72 h, and cell viability was diminished in a dose-dependent manner.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998225&req=5

f1-ol-0-0-4909: Inhibition of cell growth mediated by famitinib in BGC-823 and MGC-803 cell lines. Cells were exposed to famitinib for 24, 48 and 72 h, and cell viability was diminished in a dose-dependent manner.
Mentions: BGC-823 and MGC-803 cells were treated with famitinib (0, 0.6, 1.25, 2.5, 5.0, 10.0 and 20.0 µM) for 24, 48 and 72 h, followed by MTS assay. Famitinib inhibited cell growth in a dose-dependent manner (Fig. 1). The half maximal inhibitory concentration (IC50) values of famitinib in BGC-823 and MGC-803 cells were 3.6 and 3.1 µM, respectively. Based on these results, the IC50 and 1/2 IC50 were used for in vitro experiments.

View Article: PubMed Central - PubMed

ABSTRACT

Famitinib (SHR1020), a novel multi-targeted tyrosine kinase inhibitor, has antitumor activity against several solid tumors via targeting vascular endothelial growth factor receptor 2, c-Kit and platelet-derived growth factor receptor β. The present study investigated famitinib's activity against human gastric cancer cells in vitro and in vivo. Cell viability and apoptosis were measured, and cell cycle analysis was performed following famitinib treatment using 3-(4,5-dimethylthiazol −2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay, flow cytometry, terminal deoxynucleotidyl transferase dUTP nick end labeling assay and western blotting. Subsequently, cluster of differentiation 34 staining was used to evaluate microvessel density. BGC-823-derived xenografts in nude mice were established to assess drug efficacy in vivo. Famitinib inhibited cell proliferation by inducing cell cycle arrest at the G2/M phase and caused cell apoptosis in a dose-dependent manner in gastric cancer cell lines. In BGC-823 xenograft models, famitinib significantly slowed tumor growth in vivo via inhibition of angiogenesis. Compared with other chemotherapeutics such as 5-fluorouracil, cisplatin or paclitaxel alone, famitinib exhibited the greatest tumor suppression effect (>85% inhibition). The present study demonstrated for the first time that famitinib has efficacy against human gastric cancer in vitro and in vivo, which may lay the foundations for future clinical trials.

No MeSH data available.